key: cord-0845580-cb9qqg79 authors: Zhang, Jin; Zhang, Xiaoming; Liu, Jianhua; Ban, Yuan; Li, Na; Wu, Yunhai; Liu, Yong; Ye, Rui; Liu, Jinyang; Li, Xinghai; Li, Luping; Qin, Xiaosong; Zheng, Rui title: Serological detection of 2019-nCoV respond to the epidemic: A useful complement to nucleic acid testing date: 2020-07-30 journal: Int Immunopharmacol DOI: 10.1016/j.intimp.2020.106861 sha: 89eaf0f930211a10748d5939041f5fad675af542 doc_id: 845580 cord_uid: cb9qqg79 Corona Virus Disease 2019 (COVID-19) has spread rapidly to more than 215 countries, with over 11.91 million reported cases and more than 540,000 deaths. Rapid diagnosis remains a bottleneck for containing the epidemic. We used an automated chemiluminescent immunoassay to detect serum IgM and IgG antibodies to the 2019-nCoV in 742 subjects, so as to observe the dynamic process of antibody production in COVID-19 disease and seroepidemiology in different populations. Patients with COVID-19 were reactive (positive) for specific antibodies within 3-15 days after onset of symptoms. Specific IgM and IgG levels increased with the progression of the disease. The areas under the receiver operating characteristic curves for IgM and IgG were 0.984 and 1.000, respectively. This antibody detection assay had good sensitivity and specificity. The understanding of the dynamic serological changes of COVID-19 patients and the seroepidemiological situation of the population will be helpful to further control the epidemic of COVID-19. Coronaviruses (CoVs) are enveloped single-stranded positive-sense RNA viruses. They often cause respiratory, digestive, and nervous system diseases in humans and other mammals [1] . In the past 20 years, coronaviruses have caused two global epidemics of severe respiratory infections: the severe acute respiratory syndrome (SARS) [2, 3] However, the sensitivity of nucleic acid detection is not ideal. Due to sampling and other determinants, only 30%-50% of the confirmed COVID-19 cases had positive results on the first nucleic acid test after morbidity. In clinical practice, the highly suspicious cases with a first negative test usually were subjected to multiple nucleic acid analyses until a definitive diagnosis was found or evidence of exclusion was found. confirmed as the basis for diagnosis of suspected patients with COVID-19, that is the serum specific IgM antibody and IgG antibody positive or the serum specific IgG antibody changes from negative to positive or the recovery period is 4 times or more higher than the acute period. After viral infection, the host immune system is activated to defend against the virus, with specific antibody production. For the laboratory diagnosis of infectious diseases, the detection of virus-specific antibodies is a sensitive method. However, the antibody production against the 2019-COVID and changes during the COVID-19 progression have not been characterized. In this study, we determined specific antibody dynamics in COVID-19 patients and seroepidemiology in other populations by using an automated chemiluminescent immunoassay to evaluate antibody production during disease progression and the value of antibody detection for the laboratory diagnosis of COVID-19. A total of 742 subjects were included in the study. According to the "Diagnosis and Treatment plan of Corona Virus Disease 2019" [8], 9 confirmed COVID-19 cases from two government-designated COVID-19 treatment hospitals in Liaoning province were assigned to the COVID-19 group. 225 patients with suspected COVID-19 admitted to the fever clinic were observed in quarantine and excluded of COVID-19 after two negative results by 2019-nCoV nucleic acid testing were assigned to the non-COVID-19 group. Another 222 outpatients with other diseases during the same period, 63 medical staff at the fever clinic, and 223 healthy physical examinees in 2018 were assigned to the other disease group, medical staff group, and health control group, respectively. According to a unified form, two residents collected clinical data from medical records separately. Venous blood (5 mL) under fasting conditions was collected from all subjects and placed in a yellow-top vacuum tube containing separation gel. After centrifugation, the serum samples were stored at-20°C. Quantitative variables are expressed as medians (P99). The normality of variables was tested using the Kolmogorov-Smirnov test. LDS t-tests were used for comparisons among groups. A receiver operating characteristic curve (ROC) was plotted by the SPSS Software to evaluate diagnostic performance. All tests were two-sided and P< 0.05 was considered statistically significant. 3.1 Of the nine confirmed cases, four were male and five were female. The age of subjects ranged from 19 years to 57 years. Four patients had diabetes, hypertension, chronic kidney disease and chronic liver disease. Three were mild cases, four were severe cases and two were asymptomatic infection cases. One case had a history of contact with individuals in Wuhan, two cases had no clear epidemiological history and the other six cases were imported from abroad (Table 1 ). 3.2 The main laboratory findings for patients with COVID-19 were normal or exhibited slightly lower levels of the white blood cells and lymphocytes, elevated levels of the inflammatory indicators (e.g., interleukin-6, procalcitonin, C-reactive protein, serum amyloid A, and erythrocyte sedimentation rate), and normal myocardial marker levels ( Table 2). 3.3 Anti-2019-nCoV antibody production after the onset of symptoms has been summarized in Fig. 1 and Table 3 . Nine patients with COVID-19 showed reactivity 3.4 In non-COVID-19, other disease, medical staff, and health control groups, a few cases were reactive for 2019-nCoV IgM and IgG, all of which were single reactive for IgM or IgG. For this particular cohort , the sensitivities of IgM and IgG were 88.89% and 100%, and the specificities were both over 97% (Table 4) (Table 4 ). 3.6 We also compared the distributions of anti-2019-nCoV antibody levels among groups. The anti-2019-nCoV IgM levels were significantly higher (P<0.05) in the non-COVID-19 group than those in the healthy control group (Table 4, Fig. 2 ). With the growing surveillance network and laboratory capacity, the viral genome 2019-nCoV is highly infectious in the general population. Severe cases are prone to rapid progression to an acute respiratory distress syndrome, septic shock, high risk of admission to intensive care units, and even death [12] . Therefore, the development of methods for the close monitoring of patients and the early identification of severe cases is the key to reduce mortality. According to our findings, the time and speed of specific anti-2019-nCoV IgM antibody production were correlated with the disease severity. However, owing to the small number of cases, more research will be needed for confirmation. In addition to patients with COVID-19, those with fever and non-COVID-19, other diseases, medical staff, and healthy controls were also evaluated. Compared with RNA test, the operation requirement of serum antibody detection in clinical laboratory is lower, fast (30 min) and high throughput. The disadvantage of nucleic acid detection is the existence of relative high false negative rate, and serological antibody detection has the advantage of high sensitivity, so the combination of the two will be a good diagnostic means. It can be inferred that after the future epidemic situation has been controlled to a certain extent, as a convenient method, antibody detection is still necessary to make differential diagnosis of other respiratory pathogens infection. It must be emphasized that independent results of specific antibodies testing should not be used as a diagnostic criteria, especially when the epidemiological history is unclear, and must be combined with the patient's morbidity time and clinical signs. Little is known about specific antibody production during the course of COVID-other diseases, special contact (e.g., medical staff), and the healthy population. This study provides a detailed analysis of antibody production in the course of COVID-19 infection as well as basic data for specific antibodies in different populations. Our results provide a basis for the rapid screening of suspected cases by serological testing to curb the rapid progression of the epidemic globally. On the day this manuscript was Province, where this study was conducted, is a low-level epidemic area, the potential for asymptomatic infection is expected to be low. COVID-19 now is an urgent global medical issue that caused widely concerned. We analyzed Chinese population to study the trend of specific antibody and seroepidemiology in different population. In this paper, we first characterized specific antibody production in patients with COVID-19 and evaluated the diagnostic value of antibodies in various populations, providing key information for doctors in the process of diagnosis and treatment. As a useful complement to nucleic acid detection, the rapid, and accurate diagnostic approach to effectively distinguish between COVID and non-COVID-19 and curb the rapid spread of 2019-nCoV globally. The study was conducted in accordance with the International Coordinating Council Thank you very much for your kind letter and the good comments concerning our manuscript entitled "Serological detection of 2019-nCoV respond to the epidemic: A useful complement to nucleic acid testing" (INTIMP_2020_2234). We feel great thanks for your professional work, which have contributed a lot to improve the quality of our article. We have further revised the manuscript according to your comments. In this revised version, changes to our manuscript are highlighted by using the track changes mode in MS Word. The detailed responses are listed below each comment. The manuscript is approved by all authors for publication. I would like to declare on behalf of my co-authors that the work described was original research that has not been published previously, and not under consideration for publication elsewhere, in whole or in part. All the authors listed have approved the manuscript that is enclosed. Rui Zheng, M.D., PhD • For the first time, we have observed the seroconversion process of COVID-19 patients including severe, common and asymptomatic cases in detail and found the characteristics of specific antibody production. • We studied the specific antibody levels of different populations at the early stage of the epidemic, which provides basic information for future evaluation of the immune status of the population. • We demonstrated that automated chemiluminescent immunoassay to detect specific antibodies is an effective complementary approach with high sensitivity and specificity to diagnose COVID-19. Emerging coronaviruses: Genome structure, replication, and pathogenesis A novel coronavirus associated with severe acute respiratory syndrome Characterization of a novel coronavirus associated with severe acute respiratory syndrome We thank Prof. Qijun Wu (Department of Epidemiology, Shengjing Hospital of China Medical University) for his guidance in statistical analysis.